These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 31203816)

  • 1. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
    Wallach JD; Luxkaranayagam AT; Dhruva SS; Miller JE; Ross JS
    BMC Med; 2019 Jun; 17(1):117. PubMed ID: 31203816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
    Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
    JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
    Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
    BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
    Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
    Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
    Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
    JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
    Miller JE; Korn D; Ross JS
    BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence.
    Moneer O; Brown BL; Avorn J; Darrow JJ; Mitra-Majumdar M; Joyce KW; Ross M; Pham C; Kesselheim AS
    Drug Saf; 2022 Apr; 45(4):305-318. PubMed ID: 35182362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.
    Naci H; Smalley KR; Kesselheim AS
    JAMA; 2017 Aug; 318(7):626-636. PubMed ID: 28810023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
    Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
    BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies.
    Mooghali M; Wallach JD; Ross JS; Ramachandran R
    JAMA Netw Open; 2024 Aug; 7(8):e2430486. PubMed ID: 39190303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients.
    Dauner DG; Dauner KN; Peterson ALH
    Res Social Adm Pharm; 2020 Jun; 16(6):844-847. PubMed ID: 31812502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study.
    Zeitoun JD; Ross JS; Atal I; Vivot A; Downing NS; Baron G; Ravaud P
    BMJ Open; 2017 Dec; 7(12):e018587. PubMed ID: 29273664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
    Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
    Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy and newly approved cancer drugs - A quantitative analysis of registered protocols for drugs approved for the treatment of solid tumors.
    Rabe L; Wenz F; Ehmann M; Lohr F; Hofheinz RD; Buergy D
    Radiother Oncol; 2022 Mar; 168():69-74. PubMed ID: 35101471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
    Zou CX; Becker JE; Phillips AT; Garritano JM; Krumholz HM; Miller JE; Ross JS
    Trials; 2018 Oct; 19(1):581. PubMed ID: 30352601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. US FDA Postmarketing Requirements and Commitments: A Systematic Assessment of Clinical Pharmacology Studies and Their Impact on US FDA Prescribing Information.
    Ridge S; Guinn D; Pfuma Fletcher E; Zineh I; Madabushi R; Ramamoorthy A
    J Clin Pharmacol; 2023 Jun; 63(6):695-703. PubMed ID: 36731882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.